Mithra: information on the total number of voting rights

 

Regulated information – In accordance with article 15 of the Act of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 2,672,414 new shares on 4 June 2018 in the framework of the private placement publicly announced on 31 May 2018

  • Share capital: €27,555,760.70
  • Total number of securities carrying voting rights: 37,639,495 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,639,495 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued: 650 warrants issues on 2 March 2015, entitling their holders to subscribe for a total number of 1,072,500 securities carrying voting rights (all ordinary shares)

Note

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?